AI assistant
Sending…
Dr. Lal Pathlabs Limited — Remuneration Information 2021
Nov 1, 2021
61783_rns_2021-11-01_c538dac1-2246-4868-8780-db28befa23fc.pdf
Remuneration Information
Open in viewerOpens in your device viewer
==> picture [23 x 48] intentionally omitted <==
==> picture [252 x 28] intentionally omitted <==
==> picture [152 x 61] intentionally omitted <==
| SI.No.a)b) | Particulars | Details | |
|---|---|---|---|
| Brief details of Optionsgrante~ | 4,500 (Four Thousand and FiveHundred ·Only)Optionshavebeen granted by the Nomination&RemunerationCommitteeonNovember1, 2021. | ||
| Whether the schemeisintermsofSEBI(SBEB)Regulations,2014(if applicable) | Yes | ||
| c) | Total number of shares covered by theseOptions | 4,500 (Four Thousand and FiveHundred Only) equity sharesofface valueofRs. 10/- each fullypaid-up | |
| d) | Pricing formula | Exercise price ofRs. 10/- peroption | |
| e) | Optionsvested | Not applicable | |
| f) | Time within which Option may beexercised | 5 yearsfromthe date of vesting | |
| g) | Options exercised | Not applicable | |
| h) | Moneyrealized by exercise ofOptions | Not applicable | |
| i) | The total number of shares arising as a resultofexercise ofOption | Not applicable | |
| j) | Optionslapsed | Not applicable | |
| k) | Variation of termsofOptions | There isnovariation | |
| I) | Brief details of significant terms | Only vestedOptions canbeexercisedwithintheexerciseperiod. Options shall vest after 1year but within 4 years from thedate of grant subject satisfactionof vesting conditions. Options notexercised within exercise periodshall lapse. | |
| m) | Subsequentchangesorcancellation orexercise ofsuchOptions | Thereisnochange, cancellationor exercise. | |
| n) | Diluted earnings per share pursuant to issueof equitysharesonexercise of Options | Opfions are yet tobeexercised |
==> picture [83 x 82] intentionally omitted <==
==> picture [79 x 70] intentionally omitted <==
More from Dr. Lal Pathlabs Limited
Regulatory Filings
2026
May 13
Regulatory Filings
2026
May 13
Call Transcript
2026
May 6
Regulatory Filings
2026
May 4
Regulatory Filings
2026
May 4
M&A Activity
2026
May 1
Report Publication Announcement
2026
May 1
Regulatory Filings
2026
Apr 30
Investor Presentation
2026
Apr 30
Earnings Release
2026
Apr 30